Form D · Biotechnology
Palimpsest Bio Corp.
Las Vegas, NV · CIK 0002162952
Offering snapshot reported Oct 30, 2026 · SEC filing
- Reported sold
- $172K Offering amount: $1M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Jun 27, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 30, 2026 | Initial | $172,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-603151
Simple Agreement for Future Equity (SAFE)
Source: Form D, filed Oct 30, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Matthew Davin Korpela | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4525 Dean Martin Dr. #2006
Las Vegas, NV, 89103
Las Vegas, NV, 89103